6781-29-9

Usage

Uses

Used in Pharmaceutical Industry:
(2-Methoxyphenoxy)acetonitrile is used as a key intermediate for the synthesis of various pharmaceuticals, contributing to the development of new drugs and therapeutic agents. Its unique chemical structure allows for the creation of diverse medicinal compounds, enhancing the range of treatments available for various health conditions.
Used in Agrochemical Industry:
In the agrochemical sector, (2-Methoxyphenoxy)acetonitrile is utilized as a vital component in the production of pesticides, herbicides, and other crop protection agents. Its incorporation into these products helps improve their effectiveness in protecting crops from pests and diseases, ensuring higher yields and food security.
Used in Fine Chemicals Production:
(2-Methoxyphenoxy)acetonitrile is employed as an essential intermediate in the synthesis of fine chemicals, which are high-purity chemicals used in various applications such as fragrances, dyes, and flavorings. Its presence in these products ensures their quality and performance, meeting the stringent requirements of the industry.
Used in Materials Science:
In the field of materials science, (2-Methoxyphenoxy)acetonitrile is used for the development of advanced materials with unique properties. Its versatility allows for the creation of materials with improved characteristics, such as enhanced stability, reactivity, or selectivity, which can be applied in various industries, including electronics, automotive, and aerospace.
Used in Specialty Chemicals Manufacturing:
(2-Methoxyphenoxy)acetonitrile is utilized as a critical component in the production of specialty chemicals, which are high-value chemicals with specific applications in industries such as coatings, adhesives, and sealants. Its presence in these products ensures their performance and durability, meeting the demands of specialized applications.

Upstream product

• 107-14-2 chloroacetonitrile 
• 90-05-1 2-methoxy-phenol 
• 590-17-0 cyanomethyl bromide 
• 1836-62-0 2-(2-methoxy-phenoxy)-ethylamine 
• 1878-85-9 (2-methoxyphenoxy)acetic acid 
• 22821-76-7 4-(methylsulfonyl)benzonitrile 

Downstream Products

• 67386-40-7 2-(2-methoxyphenoxy)acetimidamide hydrochloride 
• 68960-51-0 2-(2-methoxy-phenoxymethyl)-4,5-dihydro-1H-imidazole; hydrochloride 
• 137987-88-3 1-(2,4-Dihydroxy-phenyl)-2-(2-methoxy-phenoxy)-ethanone 
• 261362-95-2 Isonicotinic acid [1-amino-2-(2-methoxy-phenoxy)-eth-(E)-ylidene]-hydrazide 
• 137988-01-3 7-Hydroxy-3-(2-methoxy-phenoxy)-chromen-4-one 
• 137988-17-1 Acetic acid 3-(2-methoxy-phenoxy)-4-oxo-4H-chromen-7-yl ester 
• 201287-60-7 methyl 3-(1-imino-2-{2-methoxyphenoxyl}-ethylamino)-4-methoxybenzoate 

Relevant academic research and scientific papers

Decarboxylative Cyanation of Aliphatic Carboxylic Acids via Visible-Light Flavin Photocatalysis

An operationally simple method is disclosed for the decarboxylative cyanation of aliphatic carboxylic acids at room temperature. Riboflavin tetraacetate, which is an inexpensive organic photocatalyst, promotes the oxidation of carboxylic acids upon visible-light activation. After decarboxylation, the generated radicals are trapped by TsCN, yielding the desired nitriles without any further additive, in a redox-neutral process. Importantly, this protocol can be adapted to flow conditions.

"Nanorust"-catalyzed benign oxidation of amines for selective synthesis of nitriles

Organic nitriles constitute key precursors and central intermediates in organic synthesis. In addition, nitriles represent a versatile motif found in numerous medicinally and biologically important compounds. Generally, these nitriles are synthesized by traditional cyanation procedures using toxic cyanides. Herein, we report the selective and environmentally benign oxidative conversion of primary amines for the synthesis of structurally diverse aromatic, aliphatic and heterocyclic nitriles using a reusable "nanorust" (nanoscale Fe2O3)-based catalysts applying molecular oxygen.

Carbazolyl-substituted ethanolamines as selective beta -3 agonists

PCT No. PCT/US97/15230 Sec. 371 Date May 4, 1998 Sec. 102(e) Date May 4, 1998 PCT Filed Aug. 28, 1997 PCT Pub. No. WO98/09625 PCT Pub. Date Mar. 12, 1998Disclosed herein are selective beta 3 adrenergic agonists represented by the following structural formula: The variables in the structural formula shown above are defined in the specification. Also disclosed are methods of using these compounds for agonizing the beta 3 adrenergic receptor in patients in need of such treatment, for example, patients in need of treatment for obesity or Type II diabetes.